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Background: Yunnan is one of the provinces hardest-hit by HIV in China. To understand HIV epidemic dynamics
and evaluate prevention effectiveness, we studied the changing trends in HIV-1 prevalence and incidence among
five sub-populations in Yunnan.
Methods: Consecutive sentinel surveillances were conducted among people who inject drugs (PWID), male sexually
transmitted diseases (STD) clinic attendees, and pregnant women for 2001–2010,female sex workers (FSWs) for
2007–2010, men who have sex with men (MSM) for 2008–2010. For the newly diagnosed HIV-seropositive samples, the
recent infections were determined with BED-capture enzyme immunoassay (BED-CEIA), based on which HIV incidence
was calculated for each sub-population using McDougal algorithm.
Results: From 231,117 individuals, 6,107 HIV-positive samples were tested with BED-CEIA, among which 964 samples
were identified as recent infections. In PWID, HIV prevalence for 2001–2010 was between 27.16% and 18.35%, while the
estimated incidence rate significantly decreased from 11.68% in 2001 to 1.70% in 2010. Among male STD clinic
attendees, both the HIV prevalence (from 3.62% in 2001 to 1.73% in 2010) and incidence (from 1.10% in 2001 to
0.40% in 2010) showed a significant decreasing trend. In FSWs, the HIV prevalence for 2007–2010 kept stable (between
2.46% and 1.95%), while the HIV incidence significantly decreased (from 0.71% in 2007 to 0.31% in 2010). In MSM, the
HIV prevalence (between 11.78% and 9.42%) and incidence (between 6.01% and 8.38%) remained stable at a relatively
high level for 2008–2010. In pregnant women, the HIV prevalence (between 0.44% and 0.30%) and incidence (between
0.15% and 0.08%) remained stable for 2001–2010.
Conclusion: The HIV incidences in PWID, male STD clinic attendees and FSWs showed the decreasing trend, supporting
a positive effect of prevention strategies for these sub-populations. MSM with the highest HIV incidence have become
the sub-population most at risk. In most sub-populations, the HIV prevalence did not decline, suggesting the disease
burden is still heavy. These findings are valuable for developing HIV prevention strategies in Yunnan.
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Yunnan is located in Southwest China and situated
along the drug trafficking routes channeling heroin into
China from Southeast Asia’s opium-producing “Golden
Triangle” region [1]. Since the first HIV epidemic in
China was identified among people who inject drugs
(PWID) in Yunnan in 1989, Yunnan has been one of the
areas hardest hit by HIV in China [2]. By the end of
2010, the cumulative number of reported HIV infectors
and AIDS patients (HIV/AIDS) in Yunnan was 83,925,
accounting for 21.0% of the total national figure [3]. Fur-
thermore, Yunnan serves as a primary entry point for
the introduction of different HIV-1 genotypes into China
[4-6]. Thus, Yunnan is accepted as an epicenter of the
HIV-1 epidemic in China [2,7].
Usually, prevalence and incidence are used to describe
the characteristic of HIV epidemic in a given population.
Prevalence is the number of people living with HIV in-
fection at a given time, including recent and long-term
infections. Prevalence is most useful for measuring the
burden of HIV in a population. However, incidence is
the number of new HIV infections that occur during a
given year. HIV incidence reflects the level of on-going
HIV transmission, HIV infection trends, and the impact
of HIV prevention efforts. Traditionally, HIV incidence
estimation can be obtained through a prospective cohort
study, in which participants are repeatedly tested. How-
ever, such surveillances are difficult to establish and
costly to maintain. And cohort studies cannot avoid
some of the biases inherent, such as the loss to follow-
up and the change of participant behavior following risk-
reduction counseling [8]. Alternatively, laboratory-based
incidence assays have been developed since 1998 [9,10].
Among these methods, the BED-capture enzyme im-
munoassay (BED-CEIA) was the most commonly used
incidence assay, which is based on measurement of the
proportion of HIV-1-specific IgG to total IgG after sero-
conversion [11]. After the introduction of BED-CEIA
into China in 2005, the correction factors were reset
based on the characteristics of Chinese population [12].
The related studies showed that the HIV-1 incidence es-
timates yielded by BED-CEIA were similar to those ob-
tained by cohort studies in China [12-14]. Yunnan was
one of the provinces that earlier adopted BED-CEIA for
HIV-1 incidence surveillance.
In China, the national comprehensive surveillance for
HIV epidemic includes the national HIV sentinel surveil-
lance system, HIV/AIDS case reporting system, and
special epidemiologic surveys [15,16]. HIV sentinel sur-
veillance is a series of cross-sectional surveys on risk be-
haviors and sero-testing in the representative areas and
populations. The data from sentinel surveillance are used
to analyze the trend of HIV prevalence and the risk factors
for HIV infection in a giving region and population. Thenational sentinel surveillance sites have been estab-
lished since 1995 [16]. With development, the national
sentinel surveillance sites covers STD clinic attendees,
female sexual workers (FSWs), PWID, long-distance
truck drivers, pregnant women, paid blood donors,
men who have sex with men (MSM), clients of female
sex workers and tuberculosis (TB) patients [15,16]. To
improve the coverage, some provincial sentinel surveil-
lance sites were also established. These sentinel surveil-
lance sites improved the ability to evaluate the HIV
epidemic in China. Otherwise, the web-directed HIV/
AIDS case reporting system started to run from March
2005. According to the regulation for HIV/AIDS cases
reporting, all newly identified HIV/AIDS cases by con-
firmatory HIV testing are required to be reported into
the system within 24 hours.
However, the present surveillance can not directly pro-
vide the HIV incidence, which is vital to understand
HIV transmission dynamics and evaluate prevention ef-
fectiveness. To improve the utilization of the data, the
combination of epidemiological surveillance and labora-
tory assay may be a good choice. In this study, BED-CEIA
was used to detect recent infection with the samples from
sentinel surveillance for 2001–2010 in Yunnan, including
PWID, male STD clinic attendees, FSWs, MSM and preg-
nant women. This study explored the HIV prevalence and
incidence trends from 2001 to 2010 in Yunnan, and is im-
portant to direct the future prevention and control efforts.
Methods
Sample collection and serological testing
By 2010, 90 sentinel sites were set up for regular surveil-
lance among PWID (24 Sites; sample size: 400 per site),
male STD clinic attendees (15 Sites; sample size: 400 per
site), pregnant women (15 Sites; sample size: 400 per
site), FSWs (32 Sites; sample size: 400 per site), and
MSM (4 Sites; sample size: 200 per site) in Yunnan
Province. Consecutive sentinel surveillances were con-
ducted each year among PWID, male STD clinic attendees
and pregnant women between 2001 and 2010, among
FSWs between 2007 and 2010, among MSM between
2008 and 2010. Each participant received an anonymous
interview to collect information on demographic details
and HIV transmission related risk behaviors and provided
2–3 ml of whole blood. Plasma was separated from whole
blood for HIV testing. Samples were screened for HIV-1
antibody with an enzyme immunoassay or rapid test, and
then HIV-1 infection status was confirmed with a Western
blot assay (HIV BLOT 2.2, MP Diagnostics, Singapore).
All HIV tests were informed and voluntary. Written
consents were obtained from all participants. The study
was approved by Biomedical Ethics Review Committee
of Yunnan Province.
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Excluding previously reported HIV-seropositive sam-
ples, the newly diagnosed HIV-seropositive samples
were subjected to BED-CEIA testing. The BED-CEIA
was performed according to the manufacturer’s instruc-
tions (Calypte HIV-1 BED incidence EIA, Calypte
Biomedical Corporation, Portland, OR). Appropriate cali-
brator and negative control, low positive control and high
positive control were run in triplicate for every plate.
Test specimens were initially run singly. The optical
density (OD) values of test specimens were normalized
by a ratio using a calibrator (specimen OD/calibrator
OD) to minimize inter-run variations. If the normalized
OD (ODn) was >1.2, the specimen was classified as be-
ing from a long-term seroconverter. Specimens with
ODn <1.2 were tested again in triplicate to confirm the
values. In confirmatory testing, specimens with ODn
values <0.8 were considered to have undergone recent
seroconversion.
Calculation of incidence
HIV incidence rate was calculated using McDougal for-
mula [17]:
I ¼ F  365=wð Þ  R
N þ F  365=wð Þ  R=2 100%
Where I is the annual HIV-1 incidence; F is the cor-
rection factor; w is the window period (the mean length
of time individuals remain classified as “recently in-
fected” by BED-CEIA; in China, w = 168 days) [12]; R is
the number of recent HIV infections detected by BED-
CEIA; N is the total number of HIV-seronegative
subjects.
The correct factor was calculated using the following
formula [17]:
F ¼ R=Pð Þ þ γ−1
R=Pð Þ  a−βþ 2γ−1ð Þ  100%
Where R is the number of recent HIV infections
detected by BED-CEIA; P is the total number of HIV-
seropositive subjects that should be detected with BED-
CEIA; α is the sensitivity of BED-CEIA for recent infection
(<1 week); β is the specificity of BED-CEIA for the sam-
ple whose infected time between 1 week and 2 weeks; γ is
the specificity of BED-CEIA for the sample whose infected
time beyond 2 weeks. In China, α = 0.8098, β = 0.7571 and
γ = 0.9315 [12].
When only a part of samples are detected by BED-
CEIA among all the samples that should be detected, the
number of recent HIV infections is adjusted using the
following formula: R = R′ × (P′/P). Where R′ is the num-
ber of recent HIV infections actually determined by BED-
CEIA, P′ is the number of HIV-seropositive samplesactually detected with BED-CEIA, p is the number of
HIV-seropositive subjects that should be detected with
BED-CEIA.
The 95% confidence interval (CI) for the incidence es-




According to the Operations Manual for HIV-1 Recent
Infections Surveillance issued by Chinese Center for
Disease Control and Prevention, the estimated inci-
dence is unreliable if the number of recent infections
identified by BED-CEIA is less than 10. For pregnant
women, the number of recent infections for each year
was less than 10, a solution was to combine the data of
every two years to calculate the incidence. For the other
four sub-populations, the incidences for each year were
calculated.
Statistical analysis
Statistical analyses were conducted using the SPSS 19.0
statistical analysis software package (SPSS Inc. Chicago,
IL). Categorical variables were compared using χ2 tests.
Trend tests were performed using χ2 tests with linear-
by-linear association. All tests were two-tailed and a p-
value <0.05 was considered statistically significant.
Results
A total of 231,117 subjects were tested for HIV in senti-
nel surveillance program between 2001 and 2010, in-
cluding 25,654 PWID, 48,125 male STD clinic attendees,
110,126 pregnant women, 45,604 FSWs (2007–2010)
and 1,611 MSM (2008–2010). Through serum screening,
HIV-1 antibodies were identified in 8,432 samples, in
which 1,991 subjects had been reported as HIV-1 infec-
tion before participating in the sentinel surveillance pro-
gram. All the newly reported HIV-1 infected subjects
were confirmed with western blot assay. Except 334
samples whose volumes were not enough for BED-
CEIA, a total of 6,107 samples (94.8%) were tested with
BED-CEIA, among which 964 samples were identified as
HIV-1 recent infection. Based on these, the prevalence
and incidence estimates were obtained for each of the
five sub-populations (Table 1).
PWID
The HIV prevalence and the estimated HIV incidence
from 2001 to 2010 among PWID were shown in Table 1.
The HIV prevalence did not show a decreasing trend
(trend test, p = 0.051). However, the HIV incidence
showed a significant decreasing trend for 2001–2010
(trend test, p < 0.01).
Table 1 HIV-1 prevalence and incidence from sentinel surveillance
Population Year The number
of subjects

















PWID 2001 1344 365 27.16 (24.37 ~ 29.94) 0 345 72 11.68 (9.06 ~ 14.30)
2002 1651 379 22.96 (20.64 ~ 25.27) 0 378 100 12.96 (10.42 ~ 15.50)
2003 2212 475 21.47 (19.54 ~ 23.40) 9 464 52 2.74 (1.99 ~ 3.48)
2004 2331 531 22.78 (20.84 ~ 24.72) 12 517 76 5.23 (4.06 ~ 6.40)
2005 3008 561 18.65 (17.11 ~ 20.19) 33 503 55 2.07 (1.54 ~ 2.60)
2006 2338 491 21.00 (19.14 ~ 22.86) 171 284 32 1.80 (1.21 ~ 2.39)
2007 2416 571 23.63 (21.70 ~ 25.57) 223 331 39 2.18 (1.52 ~ 2.85)
2008 2691 563 20.92 (19.19 ~ 22.65) 162 338 38 1.94 (1.38 ~ 2.51)
2009 4626 1314 28.40 (26.87 ~ 29.94) 717 586 66 1.87 (1.42 ~ 2.32)
2010 3037 633 20.84 (19.22 ~ 22.47) 318 307 38 1.70 (1.17 ~ 2.24)
Male STD clinic attendees 2001 3922 142 3.62 (3.03 ~ 4.22) 0 140 27 1.10 (0.69 ~ 1.52)
2002 5222 122 2.34 (1.92 ~ 2.75) 0 120 27 0.88 (0.55 ~ 1.22)
2003 5419 135 2.49 (2.07 ~ 2.91) 0 123 18 0.47 (0.26 ~ 0.68)
2004 5627 113 2.01 (1.64 ~ 2.38) 3 101 18 0.52 (0.29 ~ 0.75)
2005 5611 89 1.59 (1.26 ~ 1.92) 0 85 15 0.41 (0.21 ~ 0.62)
2006 5636 88 1.56 (1.24 ~ 1.89) 0 60 10 0.37 (0.18 ~ 0.56)
2007 4989 83 1.66 (1.31 ~ 2.02) 5 76 10 0.24 (0.09 ~ 0.38)
2008 4956 67 1.35 (1.03 ~ 1.68) 5 55 8 0.23 (0.08 ~ 0.38)
2009 3731 50 1.34 (0.97 ~ 1.71) 23 26 8 0.42 (0.13 ~ 0.70)
2010 3012 52 1.73 (1.26 ~ 2.20) 19 32 7 0.40 (0.11 ~ 0.69)
FSWs 2007 11775 290 2.46 (2.18 ~ 2.75) 21 255 50 0.71 (0.52 ~ 0.90)
2008 11604 226 1.95 (1.69 ~ 2.20) 12 202 32 0.40 (0.27 ~ 0.54)
2009 12465 276 2.21 (1.95 ~ 2.48) 125 140 25 0.32 (0.20 ~ 0.44)
2010 9760 217 2.22 (1.93 ~ 2.52) 105 112 20 0.31 (0.17 ~ 0.44)
MSM 2008 450 53 11.78 (8.61 ~ 14.95) 0 53 14 6.01 (2.86 ~ 9.16)
2009 467 44 9.42 (6.64 ~ 12.21) 2 42 15 6.58 (3.25 ~ 9.90)













Table 1 HIV-1 prevalence and incidence from sentinel surveillance (Continued)
Pregnant women 2001-2002 20032 60 0.30 (0.22 ~ 0.38) 0 53 10 0.09 (0.04 ~ 0.14)
2003-2004 23254 102 0.44 (0.35 ~ 0.52) 1 94 15 0.09 (0.05 ~ 0.14)
2005-2006 23795 102 0.43 (0.35 ~ 0.51) 0 87 13 0.08 (0.04 ~ 0.12)
2007-2008 26010 108 0.42 (0.34 ~ 0.49) 1 98 15 0.08 (0.04 ~ 0.12)
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For male STD clinic attendees, the HIV prevalence and
the estimated HIV incidence were shown in Table 1.
Both the HIV prevalence and incidence among male
STD clinic attendees showed a significant decreasing
trend for 2001–2010 (trend test, p < 0.01).
FSWs
In 2007, 14 additional FSWs sentinel surveillance sites
were established, which improved monitoring HIV epi-
demic among this sub-population in Yunnan [7]. Thus,
the FSWs surveillance data from 2007 to 2010 were used
for analysis. From 2007 to 2010, the HIV prevalence and
the estimated HIV incidence in FSWs were shown in
Table 1. The HIV prevalence in FSWs kept stable (trend
test, p = 0.431). However, the HIV incidence in FSWs
showed a significant decreasing trend for 2001–2010
(trend test, p < 0.01).
MSM
Province-wide MSM sentinel surveillance initiated in
2008. From 2008 to 2010, the HIV prevalence and the
estimated HIV incidence in MSM were shown in Table 1.
The HIV prevalence and incidence in MSM showed no
significant change and remained stable at a relatively
high level for 2008–2010 (trend test, p = 0.492 and p =
0.165).
Pregnant women
For pregnant women, the surveillance data of every two
years were merged to estimate the incidence from 2001
to 2010, the HIV prevalence and the estimated HIV inci-
dence in pregnant women were shown in Table 1. The
HIV prevalence and incidence in pregnant women
remained stable for 2001–2010 (trend test, p = 0.552 and
p = 0.190).
Discussion
In this work, we first reported the province-wide appli-
cation of BED-CEIA to estimate HIV-1 incidence among
five sub-populations in China. To our knowledge, the
study period of this work is the longest, and the sample
size is the largest in China, which includes 10-year senti-
nel surveillance data and provides the trends of HIV-1
prevalence and incidence among five sub-populations
for 2001–2010 in Yunnan, one of the provinces hardest-
hit by HIV in China. The finding of this work is import-
ant to understand HIV-1 epidemic and evaluate the
measures of HIV prevention and control in the first
10 years of this century in Yunnan.
In 1989, the first HIV epidemic in Yunnan was identi-
fied among PWID in Ruili County bordering Myanmar.
Since then, PWID had become the prime force to drive
the development of HIV epidemic in Yunnan [2,7].Surveillance data showed that the average prevalence
among PWID increased from 1992 to 1999 (2.7% in
1992, 15.0% in 1995 and 30.0% in 1999) [7]. The data
from reported cases showed that the intravenous injec-
tion had been the premier transmission route until 2006
[2,7]. In this study, we found that the estimated HIV in-
cidence rate among PWID remained around 12% from
2001 to 2002. In 2003, it significantly decreased. After
2005, it remained near 2%. The significant decrease of
HIV incidence rate among PWID could result from the
implement of the needle exchange programs (NEPs, in-
troduced in 2002) and methadone maintenance treat-
ment (MMT, introduced in 2004) [18-20]. Based on a
mathematical transmission model, it was estimated that
NEPs in Yunnan have averted approximately 16-20%
(5,200-7,500 infections) of the expected HIV cases from
2002 to 2008 [21]. However, the prevalence among
PWID remained stable at a high level during the study
period, and was the highest among four high-risk
groups. Moreover, HIV prevalence among PWID in
Yunnan was two times of the national average level in
this population for 2001–2010 [3]. The life cycle of
PWID extended with the introduction of a nationally
subsidized antiretroviral therapy program in 2004. Thus,
the infected PWID would be repeatedly recruited in the
sentinel surveillance. Meanwhile, more previously un-
detected infections were found with the expanding HIV
testing in Yunnan. All of these could attenuate the con-
tribution of the incidence decreasing.
A part of male STD clinic attendees were reported to
visit FSWs [22]. As the important bridging populations,
FSWs and male STD clinic attendees played an import-
ant role in driving sexual transmission and the transition
of the epidemic from high-risk population to general
population. Because of the limitation of surveillance
data, the estimation of HIV epidemic in FSWs was per-
formed only from 2007 to 2010 in this study. Neverthe-
less, the both HIV incidence rates among FSWs and
male STD clinic attendees showed decreasing trend,
which may related with the promotion of condom use
and health education [23], which was introduced in
2002. According to the data of FSWs integrated inter-
vention in Yunnan, HIV knowledge awareness rate in-
creased from 82% in 2007 to 95% in 2010. More FSWs
consistently used condom with clients in the last month
(75% in 2007; and 86% in 2010) and in the last commer-
cial sex (92% in 2007; and 94% in 2010). Male STD clinic
attendees were the only population in which the HIV
prevalence significantly decreased. Besides the decrease
of incidence rate, there are other possible reasons. Be-
cause most STDs are curable, some STD clinic attendees
infected with HIV would not return to STD clinic after
their STDs were cured. This part of individuals would
not be monitored in the following years, which means
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ing the prevalence using the data from the sentinel sites
of Male STD clinic attendees.
In recent years, a fast-spreading HIV epidemic among
MSM brings a new challenge to China. The national
HIV prevalence from MSM sentinel surveillance data
showed a rising trend from 0.9% in 2003 to 6.3% in 2011
[24]. In this study, we found HIV prevalence from MSM
sentinel surveillance in Yunnan was about 10% from
2008 to 2010, which suggested that Yunnan bears higher
HIV burden in the MSM population. Strikingly, the HIV
incidence in MSM was the highest among the five sub-
populations and reached 8.38% in 2010. Although the
HIV prevalence and incidence in MSM showed no sig-
nificant change for 2008–2010, based on the HIV/AIDS
case reporting system, the annual proportion of newly
reported HIV cases attributed to homosexually transmit-
ted infection in Yunnan increased (6.1% in 2008, 9.1% in
2009 and 12.0% in 2010), which may result from scaling
up HIV testing among this population. Usually, MSM
are difficult to access because of their underground
behaviors and mobile lifestyles. From 2007, the interven-
tion provided by peer educators from community based
organizations was introduced, which promotes HIV test-
ing, active care and antiretroviral therapy of HIV-
positive MSM [25]. Presently, the epidemic in MSM is
in the ascending period, more attention should be given
to this sub-population.
HIV prevalence in pregnant women can be representa-
tive of that in the general population [26]. The data from
pregnant women had been used to compare the regional
variation of HIV epidemic [27,28]. Our study found that
the HIV prevalence and incidence in pregnant women
showed no significant change for 2001–2010, which sug-
gested that HIV transmission between spouses and sex-
ual partners was relatively stable.
According to the data of reported cases, the main
transmission route changed from intravenous injection
to sexual contact after 2006 [7]. According to the HIV/
AIDS case reporting system, among the annual newly re-
ported HIV cases, the proportion of the individuals in-
fected by heterosexual contact continually increased
from 30.6% in 2006 to 58.4% in 2010. However, the in-
crease of the proportion of the sexual transmission did
not convince the decreasing incidence observed in senti-
nel surveillance from the heterosexual transmission re-
lated populations, such as FSWs and male STD clinic
attendees. The possible explanation may be that the HIV
epidemic has transited from the high-risk populations to
the general population, in which non-commercial sexual
behaviors might be more prevalent than commercial
sexual behaviors. Because the scale of the general popu-
lation is larger than that of the high-risk populations,
even if the incidence is low, the number of HIV-infectedindividuals will be larger. Furthermore, the more HIV-
infected individuals previously undetected were found
with increasing HIV testing(The total annual number for
HIV testing increased from 95,755 in 2001 to 2,766,106
in 2010). Thus, the recent infection research for annual
reported cases may provide more information to evalu-
ate the epidemic in general population.
In fact, when using BED-CEIA, the misclassification
of established infections as recently acquired infections
may occur due to false-positive tests resulting from vari-
ous reasons, such as antiretroviral therapy, low CD4+ T
lymphocytes counting and HIV-1 genotypes [29]. To
correct the potential disturbance, two strategies have
been adopted. One is case-based adjustment, to exclude
long-term infections by using additional information,
such as the recorder of previous HIV testing and diagno-
sis and the number of CD4+ T lymphocytes. The other
is formula-based adjustment using local correction fac-
tors for incidence estimates. In this study, although these
two strategies have been considered, the misclassification
may not be completely avoided. However, what we really
concern is the changing trend of HIV incidence, which
directly reflects HIV transmission dynamics and preven-
tion effectiveness. With the consistent standard, the
consecutive sentinel surveillances and BED-CEIA testing
could provide the trend of HIV incidence.
Conclusions
In conclusion, our study elucidated the trend of HIV
prevalence and incidence for 2001–2010 among five
sub-populations in Yunnan. HIV incidences among
PWID, male STD clinic attendees and FSWs showed the
declining trends, which suggested that the prevention
and control efforts for these population should be con-
tinued. However, HIV incidence in MSM showed no
significant change and remained stable at a relatively
high level, which suggested that more resource should
be input and the effective measures for HIV prevention
should be developed for this population.
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